Focal therapy in prostate cancer: Determinants of success and failure

Journal of Endourology

Volumn 24, Issue 5, 2010, Pages 819-825

  Ahmed, Hashim Uddin ^a   Moore, Caroline ^a   Lecornet, Emilie ^a,b   Emberton, Mark ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; CRYOSURGERY; FOCAL THERAPY; HUMAN; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR BIOPSY; ULTRASOUND;

BIOPSY; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77952570821     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2009.0665     Document Type: Review

References (28)

1. Cooperberg MR, Moul JW, Carroll P. The changing face of prostate cancer. J Clin Oncol 2005;23:8146-8151.
2. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007;4:632-642.
3. Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities. J Urol 2007;178:2260-2267.
4. Polascik TJ, Mayes JM, Mouraviev V. Nerve-sparing focal cryoablation of prostate cancer. Curr Opin Urol 2009;19:182-187.
5. Ahmed HU, Emberton M. Active surveillance and radical therapy in prostate cancer: Can focal therapy offer the middle way? World J Urol 2008;26:457-467.
6. Roach M 3rd, Hanks G, Thames H Jr., Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974.
7. van As NJ, Parker CC. Active surveillance with selective radical treatment for localized prostate cancer. Cancer J 2007;13:289-294.
8. Ahmed HU, Moore C, Emberton M. Minimally-invasive technologies in uro-oncology: The role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol 2009;18:219-232.
9. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
10. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974. (Pubitemid 28445094)
11. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540-545.
12. Ahmed HU, Zacharakis E, Dudderidge T, et al. Highintensity- focused ultrasound in the treatment of primary prostate cancer: The first UK series. Br J Cancer 2009;101: 19-26.
13. Aus G. Current status of HIFU and cryotherapy in prostate cancer-a review. Eur Urol 2006;50:927-934.
14. Blana A, Brown SC, Chaussy C, et al. High-intensity focused ultrasound for prostate cancer: Comparative definitions of biochemical failure. BJU Int 2009;104:1058-1062.
15. StameyTA, YangN,HayAR,McNeal JE,Freiha FS, RedwineE. Prostate specific antigen as a serummarker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
16. Vesely S, Knutson T, Damber JE, Dicuio M, Dahlstrand C. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol 2003; 37:322-328.
17. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: Review of the current literature. Cancer 2008;112:1650-1659.
18. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med 2009;361:1704-1706.
19. O'Donnell H, Parker C. What is low risk prostate cancer and what is its natural history. World J Urol 2008;26:415-422.
20. Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009;27:4321-4326.
21. Turkbey B, Pinto PA, Choyke PL; Medscape. Imaging techniques for prostate cancer: Implications for focal therapy. Nat Rev Urol 2009;6:191-203.
22. Kirkham AP, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C. MR imaging of prostate after treatment with highintensity focused ultrasound. Radiology 2008;246:833-844.
23. Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S, Kamoi K, Villers A. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: Correlation with radical prostatectomy specimens. Urology 2009;74:1094-1099.
24. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006;176(6 Pt 1):2432-2437.
25. Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C, Emberton M. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009;6:197-206.
26. Atri M, Gertner MR, Haider MA, Weersink RA, Trachtenberg J. Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer. Can Urol Assoc J 2009;3:125-130.
27. Gravas S, Mamoulakis C, Rioja J, Tzortzis V, de Reijke T, Wijkstra H, de la Rosette J. Advances in ultrasound technology in oncologic urology. Urol Clin North Am 2009;36: 133-145, vii.
28. Hoyt K, Castaneda B, Zhang M, et al. Tissue elasticity properties as biomarkers for prostate cancer. Cancer Biomarkers 2008;4:213-225.